12/25
08:31 am
avbp
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
Low
Report
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
12/22
06:01 pm
avbp
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
12/22
08:55 am
avbp
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
12/22
08:00 am
avbp
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Low
Report
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
12/16
01:17 pm
avbp
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Low
Report
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
12/11
06:28 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
12/10
07:21 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/9
08:10 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/26
06:43 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
11/25
08:44 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was given a new $43.00 price target on by analysts at Truist Financial Corporation.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was given a new $43.00 price target on by analysts at Truist Financial Corporation.
11/11
03:35 pm
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its price target lowered by analysts at Citigroup Inc. from $33.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) had its price target lowered by analysts at Citigroup Inc. from $33.00 to $31.00. They now have a "buy" rating on the stock.
11/10
08:18 am
avbp
ArriVent BioPharma Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/10
08:00 am
avbp
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
Low
Report
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
10/3
03:30 pm
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.